Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 920
- Registration Number
- NCT04589845
- Locations
- 🇩🇪
Uniklinikum, Comprehensive Cancer Center Mainfranken, Würzburg, Germany
🇭🇰Hong Kong Children's Hospital, Hong Kong, Hong Kong
🇰🇷Seoul National University Hospital- Pediatric Site, Seoul, Korea, Republic of
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 192
- Registration Number
- NCT04592341
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇵🇱Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot, Poland
🇫🇷Gerontopole; Centre de Recherche clinique, Toulouse, France
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 751
- Registration Number
- NCT04586023
- Locations
- 🇺🇸
North Central Neurology Associates, Cullman, Alabama, United States
🇺🇸Xenoscience, Phoenix, Arizona, United States
🇬🇷AHEPA Univ. General Hospital of Thessaloniki, Thessaloniki, Greece
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 746
- Registration Number
- NCT04586010
- Locations
- 🇲🇽
Hospital General de Mexico, Mexico, Tlaxcala, Mexico
🇳🇱Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, Netherlands
🇲🇰Clinical Hospital Stip, Stip, North Macedonia
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Drug: Granulocyte colony-stimulating factor (G-CSF)Drug: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT04584112
- Locations
- 🇺🇸
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
🇦🇺Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia
🇧🇷Hospital Sírio-Libanês, Sao Paulo, SP, Brazil
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Paracetamol/acetaminophen
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT04580121
- Locations
- 🇮🇹
Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇩🇰Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
- Conditions
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 303
- Registration Number
- NCT04576455
- Locations
- 🇿🇦
Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa
🇿🇦Eastleigh Breast Care Centre, Pretoria, South Africa
🇨🇳Changhua Christian Hospital; Dept of Surgery, Changhua, Taiwan
Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 251
- Registration Number
- NCT04567303
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸The Retina Partners, Encino, California, United States
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT04557150
- Locations
- 🇦🇺
Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
🇧🇪UZ Gent, Gent, Belgium
🇩🇰Rigshospitalet, København Ø, Denmark
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: PRM-151 (Zinpentraxin Alfa)Drug: Placebo
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 665
- Registration Number
- NCT04552899
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸San Marcus Research Clinic Inc., Miami, Florida, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States